Myeloablative chemotherapy for chemosensitive recurrent follicular lymphoma potential
Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse by Silvia Montoto, Janet Matthews, Paul Greaves, Debra Lillington, Deborah Anderson, John G. Gribben, and T. Andrew Lister haematol Volume 98(4): 620 -625 March 31, 2013 © 2013 by Ferrata Storti Foundation
Main characteristics of the patients. Silvia Montoto et al. Haematologica 2013; 98: 620 -625 © 2013 by Ferrata Storti Foundation
Histology at relapse after BEAM according to the histology at the time of BEAM. Silvia Montoto et al. Haematologica 2013; 98: 620 -625 © 2013 by Ferrata Storti Foundation
Time-to-progression in 80 patients treated with BEAM for relapsed FL. Silvia Montoto et al. Haematologica 2013; 98: 620 -625 © 2013 by Ferrata Storti Foundation
Time-to-progression according to the number of previous treatment lines in patients who received BEAM. Silvia Montoto et al. Haematologica 2013; 98: 620 -625 © 2013 by Ferrata Storti Foundation
Prognostic factors for time-to-progression (TTP) and overall survival (OS). Silvia Montoto et al. Haematologica 2013; 98: 620 -625 © 2013 by Ferrata Storti Foundation
Triple FISH prior to HDT and treatments prior to the diagnosis of secondary myelodysplastic syndrome (s. MDS). Silvia Montoto et al. Haematologica 2013; 98: 620 -625 © 2013 by Ferrata Storti Foundation
Overall survival according to the number of previous treatment lines in patients who received BEAM. Silvia Montoto et al. Haematologica 2013; 98: 620 -625 © 2013 by Ferrata Storti Foundation
- Slides: 8